Initial clinical cases of the use of a NF-kappaB decoy at the site of coronary stenting for the prevention of restenosis.
BACKGROUND
Nuclear factor-kappaB (NF-kappaB) plays a pivotal role in restenosis after percutaneous coronary intervention (PCI) and the aim of the present clinical trials was to evaluate the effectiveness of a NF-kappaB decoy for preventing restenosis.


RESULTS
The initial case was a patient suffering from effort angina who had stenoses in the proximal and middle portions of the right coronary artery. The patient received 2 stents; the NF-kappaB decoy was delivered to the distal site, but not the proximal site. Six months after the PCI, the NF-kappaB decoy had suppressed restenosis in comparison with the no-decoy transfection site. The second case was a patient who underwent single-stent insertion and decoy transfection at the same site, and minimal intimal thickening was observed at 6 month after PCI. No systemic adverse effects were observed in either case.


CONCLUSIONS
These results indicate the clinical usefulness and safety of NF-kappaB decoy transfection after PCI, but further evaluations are necessary to confirm its clinical effectiveness.
Jun-Ichi
Suzuki
S
Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Japan.
Hiroshi
Ito
I
Ryo
Gotoh
G
Ryuichi
Morishita
M
Kensuke
Egashira
E
Mitsuaki
Isobe
I
D000328:Adult; D000787:Angina Pectoris / Q000473:pathology / Q000628:therapy; D000818:Animals; D004730:Endothelium, Vascular / Q000473:pathology; D006083:Graft Occlusion, Vascular / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D006801:Humans; D008297:Male; D016328:NF-kappa B / Q000235:genetics*; D009841:Oligonucleotides / Q000008:administration & dosage*; D015607:Stents / Q000009:adverse effects; D013552:Swine; D014162:Transfection; D018084:Ultrasonography, Interventional
D016328:NF-kappa B; D009841:Oligonucleotides